Pembrolizumab with chemo and radiation for early anal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of the immunotherapy drug pembrolizumab, two chemotherapy drugs (carboplatin and paclitaxel), and radiation for people with early-stage anal cancer who cannot take the usual chemotherapy. The goal is to see if this approach is safe and effective as an alternative treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have early-stage anal cancer (stage I, II, or certain stage III that has not spread far).
- You cannot receive the standard chemotherapy drugs (5FU and mitomycin-C) with radiation for medical reasons.
- You have not had any previous treatment for anal cancer.
- You are in generally good health (ECOG score 0 or 1) and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
This trial tests a shorter course of radiation therapy given with chemotherapy for people with high-risk anal cancer. The goal is to see if the shorter treatment is just as effective but causes fewer side effects and is more convenient.
This trial tests if giving chemotherapy before standard chemoradiation works better than standard chemoradiation alone for people with locally advanced anal cancer that has not spread. It aims to improve treatment outcomes.
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
This trial tests two immunotherapy drugs—pembrolizumab and lenvatinib—for people with advanced anal cancer that has spread or come back. The goal is to see if these drugs can help shrink or control the cancer.
Hear when a new Anal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.